Mapi Pharma
We are a clinical stage pharmaceutical company, developing complex active pharmaceutical ingredients.
Focus
Our main focus is on developing long acting depot injectable drugs.
Programs
Our lead programs are GA Depot for treating various forms of MS and long acting Pregabalin (Lyrica®) for pain.
Latest News
Viatris and Mapi Pharma Announce FDA Acceptance of New Drug Application Filing for GA Depot for the Treatment of Relapsing Forms of Multiple Sclerosis
FDA assigns PDUFA target action date of March 8, 2024 New Drug Application supported by positive Phase III efficacy and safety clinical trial results Milestone builds upon Viatris’ long-standing and continued commitment toward addressing the unmet needs of the MS...
Viatris and Mapi Pharma to Highlight Latest Results of Multiple Sclerosis Research at American Academy of Neurology 75th Annual Meeting
Meeting program to feature latest clinical findings for GA Depot and showcase commitment to improving care for people living with multiple sclerosis (MS) PITTSBURGH, April 24, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, and Mapi...